Email Updates

You are here

HIV Vaccine

There is momentum and promise in the search for an HIV vaccine.

An effective preventive HIV vaccine would teach the body how to prevent HIV infection. Vaccines are the most powerful public health tools available—and an HIV vaccine would play a powerful role in ensuring the end to the AIDS epidemic.

While effective vaccines remain years away, there are more reasons for hope than ever before. Researchers are pursuing groundbreaking research with number of vaccine strategies, including broadly neutralizing antibodies that target a wide range of HIV strains. At the same time, there is also exciting work in efforts to understand if and how to cure HIV in people who are already infected. The timeline for this work is long and uncertain. Here, too, advocacy is needed to sustain momentum.

Today’s momentum depends on sustained funding. Policy makers and funders around the world must have the courage to sustain vital HIV vaccine research for years to come, and advocates must keep the pressure on them to maintain their commitments.

What We're Reading

Historically, vaccination represents the most cost-effective, scalable, and lasting public health intervention for the eradication of infectious disease; thus, developing a safe and effective HIV-1 vaccine is a global health imperative. Importantly, an HIV-1 vaccine will be part of a multimodal array of HIV-1 prevention tools, and work on alternative preventive approaches should be extended and further developed until an effective vaccine becomes available.

September 10, 2020
PLOS Pathogens

To date, hundreds of clinical trials for HIV-1 vaccines have been tested. However, there is no HIV-1 vaccine available yet, mostly because the immune correlates of protection against HIV-1 infection are not fully understood. Currently, a variety of recombinant viruses-vectored HIV-1 vaccine candidates are extensively studied as promising strategies to elicit the appropriate immune response to control HIV-1 infection.

September 8, 2020
Vaccines

As modalities to prevent HIV infection continue to expand, from oral pre-exposure prophylaxis (PrEP) to injectable formulations, trials for HIV vaccines must take these into account and ensure that ethical principles are being followed, an expert panel said.

July 9, 2020
MedPage Today
Subscribe to RSS - HIV Vaccine